Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis May 27, 2026 8:00 AM EDT
Company Participants
Noel Kurdi – Vice President of Investor Relations
Michael Henderson – CEO & Director
Carl Dambkowski – Chief Medical Officer
Kristine Nograles – Senior Vice President of Clinical Development
Amol Kamboj
Conference Call Participants
Ruth Ann Vleugels
Tyler Van Buren – TD Cowen, Research Division
Seamus Fernandez – Guggenheim Securities, LLC, Research Division
Phoebe Tan – Jefferies LLC, Research Division
Alexander Thompson – Stifel, Nicolaus & Company, Incorporated, Research Division
Kaiyue Yang – UBS Investment Bank, Research Division
Julian Harrison – BTIG, LLC, Research Division
Presentation
Operator
Good morning, and welcome to Apogee Therapeutics Conference Call. [Operator Instructions] Please be advised that this call is being recorded at the company’s request.
I will now turn the call over to Noel Kurdi, Vice President of Investor Relations at Apogee. Noel, you may now begin.
Noel Kurdi
Vice President of Investor Relations
Thank you, operator, and thank you all for joining us today. During this call, we will be making forward-looking statements related to our current expectations and plans for the company as well as our clinical and preclinical programs. These statements represent our views as of this date and should not be relied upon as representing our views as of any subsequent date in the future.
Looking at our agenda, CEO, Michael Henderson, will begin the call with an introduction to today’s results and the opportunity in atopic dermatitis. Then Chief Medical Officer, Carl Dambkowski, will walk us through the APEX Part B initial results of zumilokibart in patients with moderate to severe atopic dermatitis. Dr. Ruth Ann Vleugels of Brigham and Women’s Hospital and Harvard Medical School will then share an update on our current treatment gaps in atopic dermatitis, followed by an overview of our zumilokibart development program by